EZH2 supports ovarian carcinoma cell invasion and/or metastasis via regulation of TGF-β1 and is a predictor of outcome in ovarian carcinoma patients

High expression of EZH2 is associated with tumor aggressiveness and poor prognosis in patients with esophageal squamous cell carcinoma treated with definitive chemoradiotherapy

(2009) Li-Ru He et al.   INTERNATIONAL JOURNAL OF CANCER

Enhancer of zeste homolog 2 downregulates E-cadherin by mediating histone H3 methylation in gastric cancer cells

(2008) Satoshi Fujii et al.   CANCER SCIENCE

Diagnostic Markers for Early Detection of Ovarian Cancer

(2008) I. Visintin et al.   CLINICAL CANCER RESEARCH

Transforming Growth Factor- 1, Transforming Growth Factor- 2, and Transforming Growth Factor- 3 Enhance Ovarian Cancer Metastatic Potential by Inducing a Smad3-Dependent Epithelial-to-Mesenchymal Transition

(2008) T.-V. Do et al.   MOLECULAR CANCER RESEARCH

Roles of the EZH2 histone methyltransferase in cancer epigenetics

(2008) Jeffrey A. Simon et al.   MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS

Repression of E-cadherin by the polycomb group protein EZH2 in cancer

(2008) Q Cao et al.   ONCOGENE

High expression of EZH2 is associated with tumor proliferation and prognosis in human oral squamous cell carcinomas

(2008) Kazunori Kidani et al.   ORAL ONCOLOGY